Call us Toll-Free
800-476-6070

Weitz & Luxenberg Facebook Weitz & Luxenberg Google Weitz & Luxenberg Twitter Weitz & Luxenberg LinkedIn
English En Français

FREE LEGAL REVIEW

First Name
Last Name
Home Phone
Work Phone
City and State
Email
Were you diagnosed with Asbestosis? Yes
Were you diagnosed with lung cancer? Yes
Were you diagnosed with Mesothelioma? yes
What is your date of diagnosis?
Additional Comments
Best time to call?

Clinical Trials for Mesothelioma Patients: Cisplatin, Imatinib Mesylate, and Pemetrexed Inclusion Criteria

Read about the inclusion criteria for a current clinical trial being conducted to study the effects of Cisplatin, Imatinib Mesylate, and Pemetrexed or patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, this study is only being conducted in Lille, France.

Inclusion Criteria:
1. A written, voluntary informed consent form must be completed prior to beginning any study procedure.

2. Patients >/= 18 years of age.

3. Histologically documented diagnosis of malignant mesothelioma.

4. Performance status 0-2 (ECOG)

5. Pts must have adequate hepatic, renal,& bone marrow function, defined as the following:(1) total bilirubin /= 1.5x10^9/L;(5) platelets>/=100 x 10^9/L.Note:Renal function is only based on serum creatinine level /= 45mg/dl.

6. Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.

7. Patients who have not received prior chemotherapy for their metastatic or recurrent unresectable malignant mesothelioma; with the exception of patients who have recurrent mesothelioma after induction chemotherapy followed by definitive treatment (surgery +/- radiotherapy). Patients must have had 2 or fewer cycles/doses of induction chemotherapy and must have had tumor response to the induction therapy.

8. Patients must have documented unresectable malignant mesothelioma (pleural or peritoneal).

9. Patients with treated brain metastasis who have stable brain disease (i.e. no steroids at least 4 weeks prior to study enrollment).

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney

Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos
Real Stories


Mesothelioma
Mesothelioma Treatments
Treatment
Clinical trials for mesothelioma
IN THIS SECTION
Imatinib Mesylate trial for mesothelioma patients
Outcomes of Imatinib against mesothelioma cancer
Recruitment data to test Imatinib on mesothelioma
Inclusion standard in Imatinib mesothelioma trial
Exclusion standard in Imatinib mesothelioma trial
Contact info for Imatinib mesothelioma study

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

Mesothelioma Lawyer

Asbestos Lawyer

Mesothelioma Attorney

Asbestos Attorney

Mesothelioma Treatment

see also:

Outcomes of Imatinib against mesothelioma cancer Projected outcomes of program to treat mesothelioma with Imatinib
Possible outcomes of Imatinib program on mesothelioma patients

Recruitment data to test Imatinib on mesothelioma Patient recruitment info for mesothelioma clinical trial with Imatinib
Mesothelioma patient recruitment info for Imatinib therapy program

Current Imatinib therapy for mesothelioma patients Current clinical trial of Imatinib therapy for mesothelioma patients
Imatinib may inhibit cancer cell growth in current mesothelioma test